Natalizumab
3 results
Applied filters
Good governance when implementing natalizumab biosimilar
11 December 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
The licence and supporting evidence for natalizumab biosimilar
14 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.